Company intelligence / Profile preview

Zhiyi Pharmaceutics

Guangzhou, Guangdong Province, China

Ownership: Private
Development stage: Phase 2

Overview

Zhiyi Pharmaceutics has advanced a pipeline of live biotherapeutic products targeting gastrointestinal and immune-related indications. Their lead candidate SK08 is in Phase 3 for IBS-D, while SK10 has shown positive safety results in a US-based Phase I trial for chemotherapy-induced diarrhea—demonstrating good tolerability and potential efficacy by reducing inflammation and supporting mucosal barrier function. The company claims several firsts globally and within China regarding regulatory progress with LBPs.

Therapeutic areas: ImmunologyOncologyGastroenterology
Modalities: Live biotherapeutic products (LBPs)ProbioticsNext-generation probiotics (NGPs)
Industry: Biotech

Drug pipeline

13 assets

SK08

12 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Zhiyi Pharmaceutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhiyi Pharmaceutics.

Explore the full profile